AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
E B v Vaccines Can Prevent Infectious Mono Nucleosis
The aim of the first trials will be to show that these vaccine candidates are safe and can reduce the burden of infectious mono nucleosis. This illness causes symptoms including extreme fatigue and fever, and affects 30 to 50 % of people who contract e b v for the first time as teen ages or young adults. On average it takes around ten years for a vaccine to run the clinical trial gauntlet. After approval, observational data would take many more years to accumulate.